DRG Market Assessment reports

Immunoglobulin A nephropathy (IgAN) is an autoimmune disease characterized by the accumulation of IgA in the glomeruli and impaired kidney function. RAAS inhibitors and SGLT-2 inhibitors are widely…

Immunoglobulin A nephropathy (IgAN) is an autoimmune disease characterized by the accumulation of IgA in the glomeruli and impaired kidney function. RAAS inhibitors and SGLT-2 inhibitors are widely…

Pancreatic cancer remains difficult to treat owing to the lack of treatment options—primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of…

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…

Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…

Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…